drugset / Trial / NCT05666635
Study of LTC004 in Subjects With Advanced Malignant Tumors
NaSequentialOpen-labelTreatment
Summary
This was a multicenter, open, multi-cohort PHASE I study, consisting of 2 phases: Phase Ia (Phase Ia dose escalation) and Phase Ib (Phase Ib multi-cohort expansion). The objective of this study was to evaluate safety, tolerability, pharmacokinetic， Pharmacodynamics and biological characteristics, and initial efficacy in advanced malignant tumors.
Timeline
- Start
- 2022-12
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LTC004 | Unknown | 3 ug/kg | — |
| Subject | LTC004 | Unknown | 15 ug/kg | — |
| Subject | LTC004 | Unknown | 45 ug/kg | — |
| Subject | LTC004 | Unknown | 90 ug/kg | — |
| Subject | LTC004 | Unknown | 180 ug/kg | — |
| Subject | LTC004 | Unknown | 270 ug/kg | — |
| Subject | LTC004 | Unknown | 360 ug/kg | — |
| Subject | LTC004 | Unknown | 450 ug/kg | — |
Indications
No indication recorded.